ImmuKnow^(TM)-Cylex检测技术在肾移植术后重症肺炎中的应用研究

The Clinical Study of ImmuKnow^(TM)-Cylex Test to Predict Severe Pneumonia in Kidney Transplant Recipients

目的探讨ImmuKnowTM-Cylex检测技术能否作为肾移植术后发生肺部感染的预警指标。方法收集17例肾移植受者的肝素钠抗凝全血46份,通过测量CD4+T细胞刺激后释放的ATP浓度来判定机体细胞免疫水平。结果肾移植术后重症肺炎发生前(移植术后两周内)组CD4+T细胞ATP值为(383.47±186.51)ng/mL,感染时组为(187.20±115.15)ng/mL,肺炎恢复后(恢复后1周内)为(427.79±177.44)ng/mL,显著低于重症肺炎发生前组,差别具有统计学意义(P<0.05);肺炎恢复后组与感染时组差别具有统计学意义(P<0.05)。结论 ImmuknowTM-Cylex细胞免疫能量测定适合于肾移植术后临床免疫状态的监测,对术后重症肺炎感染的发生有预警价值。

Objective To evaluate whether ImmuKnowTM-Cylex test could be used to predict the occurrence of severe pneumonia in kidney transplant recipients.Methods 46 heparinized blood samples were taken from 17 kidney transplant recipients.Cell-mediated immunity（CMI） was assessed by measuring the concentration of ATP released from CD4＋T cells following stimulation.One-way ANOVA test were used for analysis of data.Results The mean ATP concentration in the transplant recipients with SP was（187.2±115.15）ng/mL,significantly lower than that before the occurrence of SP（383.47±186.50）ng/mL and that after recovering from SP（427.78±177.43）ng/mL（P0.05）.Conclusion ImmuKown assay is a valuable tool in monitoring immune status in kidney transplant recipients and predicting the occurrence of severe pneumonia.